Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming in ...
Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q1 2026 Investor Letter. A copy of the ...
PLEASANTON — Bio-Rad Laboratories, setting the stage for a big expansion in the East Bay, has bought a two-building complex in Pleasanton’s Hacienda Business Park to accommodate plans for more workers ...
Bio-Rad is filing fewer patents year after year, which suggests that it is struggling to innovate and develop new products and services. The company is lagging its peers with a negative ROE, and net ...
Bio-Rad Laboratories, Inc. (BIO) is scheduled to announce Q1 earnings results on Thursday, April 30th, after market close. The consensus EPS Estimate is $1.99 (-21.7% Y/Y) and the consensus Revenue ...
Zacks Investment Research on MSN
Unlocking Bio-Rad (BIO) international revenues: Trends, surprises, and prospects
Have you looked into how Bio-Rad Laboratories (BIO) performed internationally during the quarter ending March 2026? Considering the widespread global presence of this maker of instruments used in ...
(Reuters) - Bio-Rad Laboratories on Thursday lowered its annual revenue growth forecast, given the uncertain pace of the biopharma sector's recovery and ongoing macro challenges, sending the company's ...
(Reuters) - Bio-Rad Laboratories cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients. Shares of the diagnostics ...
BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Thursday, February 13th. The company reported earnings of $2.90 per share, beating estimates of $2.90 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results